Efficacy and safety of cisplatin + docetaxel + 5-FU + leucovorin + methotrexate and epirubicin combination chemotherapy for advanced esophageal cancer.

PLoS One · 2025 · PMC12200775 · PMID 40570003

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While more advanced clinical stages tended to correlate with decreased overall survival, this trend did not reach statistical significance, possibly due to the study’s small sample size.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.